At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne®-Lucentis® Combination Therapies and Lucentis® Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.
In Brief
A Phase 2 clinical trial evaluating verteporfin, ranibizumab, and 1 other intervention for Choroidal Neovascularization and Macular Degeneration. Completed, enrolled 162 participants across 26 sites in 2 countries.
Detailed Summary
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
Study Details
Timeline
Interventions
Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
0.5 mg intravitreal injection
0.5 mg intravitreal injection